Best Q/A's from last CC for anyone who missed it: Question-and-Answer Session
Rebecca Greco
Thanks, operator. While we're waiting, James, we also have a question about, what we think our future financing might look like. Do you have any comment on that?
James Howard-Tripp
Yes. We've typically always run with relatively low amounts of money. And I think we've talked about this before. I think Matt Pietras – when Matt was with us, Matt made the comment that he was astounded that we've been able to do what we had with a small amount of money that we had actually raised and bearing in mind the $25 million, $35 million in the world in which we operate is a small amount of money. So we've been incredibly frugal and – but also incredibly effective.
In order to push on out, we clearly need to be able to throw larger amounts of money at it. So will we finance as we go down the road, yes, almost certainly. It makes sense, you have to do this. We will always bear in mind about trying to be as frugal and as soon as possible, and I think to choose the right opportunities in where to go. So that's there. But it does matter who you are, I think it's – you look at all of the extremely large companies in the world, they are still financing. So you take money when you need it. If you can take $1 and you can turn it into $3 or $5 that's smart business, that's something we will always do.
*** Even Matt saw the numbers inside and was like, "ya im stepping down" and now they have WAY less cash then before. They say they need to throw large amounts of money to succeed, but do a PP for 177K?
Operator
We do have a question now from Dipesh Patel from H.C. Wainwright.
Dipesh Patel
Great. And then in terms of the Aristotle blood test, how has testing volume looked? And what measures are you thinking about to potentially grow volume?
James Howard-Tripp
Yes. So we've started relatively slowly, notably, everything takes time until you actually get it up and get it going. So we've been positioning with a number of the groups. Most of them are beginning literally now as we go or they have been occurring over the last few weeks as it drives some out. So we would expect Q3 and then particularly Q4 to show significant volume as we drive on out. We haven't yet actually broken it out in the individual test. We typically lump it all together. But that is something that we'll do as we move on forward.
***started slow....? ITS BEEN 16 MONTHS SINCE LAUNCH LOL. At this rate things will begin to pick up by the time everyone reading this is long dead! The YELLOW highlighted portion is a going to end up being a 100% lie. Bet your life on it.
Dipesh Patel
Great. And then last question, if I may switch gears to AVRT and COC. Could you provide some color or sense on the current number of users in those programs?
James Howard-Tripp
Yes. We have, I think, it's around 3,500 users right now. I think that's correct. Yes, we have about 3,500 users right now. And good question, because the very big part with a lot of this is that's obviously repeat business.
If you're in this, you would typically be back in actual fact that even ties with the COC protocol. Patients typically come back to every three months. And right now, our average duration of people staying with us is just approximately a year. Bearing in mind that we will lose some patients in the mix and unfortunately due to the cancer. But with others, as it builds on out, we are in the process of publishing both on Aristotle as well as on the COC protocol. And so this will be the next in the papers on the glioblastoma side, and it continues to show improvements in survival rates. So really, really nice.
We presented at a conference in London. Just a short while ago, it was actually to a by invitation to neuro-oncology group, they were very interested in what came from a glioblastoma side. And it actually got an extremely good reception. So part of what we're talking about is what kind of work can we do with them, particularly as we continue to data.
*** We got a good reception at another useless confernece, things are great lol....This is so sad to read. Same stupid talking points for 5 years. Talking at conferences means NOTHING!
Dipesh Patel
Great. Thank you so much James.
James Howard-Tripp
You’re welcome.
Rebecca Greco
James, we also have a question on the webcast. Can you please give more color as to how Mercer is opening up the relationships? And can you quantify it?
James Howard-Tripp
I think the issue with all of this, while I respect so the desire to know, I think, with most of these groups, they do not want us to disclose either who we're working with or how, and to put it bluntly, the way it was given to me is, yes, that might benefit you saying who are you working with some, but it doesn't benefit the company. They're not part of your marketing yet, but they don't want to do that.
So I think of the necessity, we're probably going to be giving less absolute clarity on exactly who we're working with and how, but it is in order to be able to get the business if we start disclosing that, I know three clients right now that if we disclose two, they were would actually pull the business. So sorry, I can't directly answer that one.
***Less clarity in the future.....HOW IS THIS EVEN POSSIBLE? Seriously? All he did was ask about Mercer as many shareholders want details for years on this, but it TOP SECRET! LOL.
Rebecca Greco
Okay. And I think we're just about up to time. So, maybe one last question and it sort of relates to what you were just saying. Does the employer infrastructure look ready for scale? Are there definitive contracts executed and testing commenced? You sort of spoke a little bit about testing commencing. Do you want to maybe just give color on, what the contracts and relationships look like in a general sense?
James Howard-Tripp
Yes. Bearing in mind that, in most instances, other than pricing, no formal contracts really needed -- at the end of the day, where a clinic and we're a lab. So it isn't as if you go on out and you ink something that says this is exactly what will happen.
Contracts typically will go around pricing, confidentiality, turnaround times the likes of that. So are those in place, yes. Have we initiated testing? Yes. Will we get to talk about this more as we move forward? Yes.
But again, going back to my earlier comment, I would guide to say that in most instances, I doubt if we're going to be able to say, exactly who it is we're working with and why. We will provide information around, for example, things like test volumes as we go forward at quarters, the likes of that. Okay?
*** Yes, I'm sure they will give out testing volumes in the future just like they have been doing up to now!....BLAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAAHA!
Rebecca Greco
Yeah. Those are the questions.
Operator
Sir, there appears to be no further questions in the queue. Do you have any closing comments that you would like to finish with?
James Howard-Tripp
Yes. No, thank you. Thanks, everyone, for joining. It's actually a nice time. This is the point that we wanted to be at. It's the point that we were getting to when COVID was in the middle of all ages and actually severely disrupted a lot of things.
It's nice to be back at that point. It's nice to be back, in fact, with all of the pieces that we believe are critical to actually make this a success. And so we look forward to continuing to update you as we go. And we'll try and be as transparent as possible.
But I think as we've talked about, yes, we're probably not going to be able to say we're working with AB and C, and they have contracted this number of tests. That generally is not what people want to disclose. So thank you for timing.
***How stupid does he think all you bagholders are? So your looking forward to update things and being more transparent, but must be much less transparent as well going forward...? Remember 1 + 1 = 3!
HE PLAYING YOU ALL YOU MORONS. This is sad to see how he is playing you all its so obvious. He could not answer a single question straight forwrd and honestly. Too many lies to rememeber I guess. Cant wait till they close up shop here. Been crazy fun to watch! I didnt want you victims to lose your money so I tried to warn you. Now loook at you all... on deaths doorstep while I laugh and watch...
Rebecca Greco
Thank you.
Operator
Thank you, ladies and gentlemen. This does conclude today's conference call. You may disconnect your phone lines at this time. And have a wonderful day. Thank you for your participation.